Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EC in Mass.

This article was originally published in The Tan Sheet

Executive Summary

Massachusetts legislature supports a measure that will make emergency contraception available through pharmacists, as the state Senate and House override Gov. Mitt Romney's veto 37-0 and 139-16, respectively, Sept. 15. The act also will mandate that emergency care facilities "promptly" offer the drug to rape victims along with "medically and factually accurate written information" about emergency contraception. Gov. Romney vetoed the act in July (1"The Tan Sheet," Aug. 8, 2005, In Brief)...

You may also be interested in...



Pataki vetoes OTC Plan B

New York Gov. George Pataki (R) vetoed a bill that would have provided OTC access without parental consent to the emergency contraceptive Plan B (levonorgestrel .75 mg) Aug. 4. The "Unintended Pregnancy Prevention Act" (S 3661) passed the state Senate June 22. Pataki cited lack of protection for minors in his decision and voiced concerns that the bill "lacks several other safeguards." The Family Planning Advocates of New York State called the governor's decision "tragic." Pataki's decision follows Massachusetts Gov. Mitt Romney's (R) July 25 veto of a similar measure...

Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval

The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.

MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In

The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS098647

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel